Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 301

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 301
---
 earnings attributable to noncontrolling interest8 10 9 Net earnings attributable to AbbVie Inc.$4,278 $4,863 $11,836 Per share dataBasic earnings per share attributable to AbbVie Inc.$2.40 $2.73 $6.65 Diluted earnings per share attributable to AbbVie Inc.$2.39 $2.72 $6.63 Weighted-average basic shares outstanding1,769 1,768 1,771 Weighted-average diluted shares outstanding1,773 1,773 1,778 

The accompanying notes are an integral part of these consolidated financial statements.

51     |  2024 Form 10-K

AbbVie Inc. and Subsidiaries

Consolidated Statements of Comprehensive Income 

years ended December 31 (in millions)202420232022Net earnings$4,286 $4,873 $11,845 Foreign currency translation adjustments, net of tax expense (benefit) of $(39) in 2024, $15 in 2023 and $(10) in 2022(1,008)407 (943)Net investment hedging activities, net of tax expense (benefit) of $133 in 2024, $(109) in 2023 and $152 in 2022484 (399)555 Pension and post-employment benefits, net of tax expense (benefit) of $206 in 2024, $(6) in 2023 and $272 in 2022824 (30)1,088 Cash flow hedging activities, net of tax expense (benefit) of $16 in 2024, $(19) in 2023 and $5 in 202280 (84)— Other comprehensive income (loss)$380 $(106)$700 Comprehensive income4,666 4,767 12,545 Comprehensive income attributable to noncontrolling interest8 10 9 Comprehensive income attributable to AbbVie Inc.$4,658 $4,757 $12,536 

The accompanying notes are an integral part of these consolidated financial statements.

2024 Form 10-K   |  52

AbbVie Inc. and Subsidiaries

Consolidated Balance Sheets 

as of December 31 (in millions, except share data)20242023AssetsCurrent assetsCash and